These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

141 related items for PubMed ID: 3324168

  • 1. Inhibition of adenosine diphosphate-induced intravascular aggregation of rat platelets in vivo by 6-oxo-prostaglandin E1.
    Oyekan AO, Botting JH.
    Prostaglandins; 1987 Sep; 34(3):359-66. PubMed ID: 3324168
    [Abstract] [Full Text] [Related]

  • 2. 6-keto-prostaglandin E1 is not equipotent to prostacyclin (PGI2) as an antiaggregatory agent.
    Miller OV, Aiken JW, Shebuski RJ, Gorman RR.
    Prostaglandins; 1980 Aug; 20(2):391-400. PubMed ID: 6251513
    [Abstract] [Full Text] [Related]

  • 3. Comparison of equimolar concentrations of iloprost, prostacyclin, and prostaglandin E1 on human platelet function.
    Fisher CA, Kappa JR, Sinha AK, Cottrell ED, Reiser HJ, Addonizio VP.
    J Lab Clin Med; 1987 Feb; 109(2):184-90. PubMed ID: 2433373
    [Abstract] [Full Text] [Related]

  • 4. Conversion of prostacyclin to 6 oxo prostaglandin E1 by rat, rabbit, guinea-pig and human platelets.
    Griffiths RJ, Moore PK.
    Br J Pharmacol; 1983 Oct; 80(2):395-402. PubMed ID: 6360281
    [Abstract] [Full Text] [Related]

  • 5. A comparison of the effects of prostacyclin and 6-keto-prostaglandin E1 on renin release in the isolated rat and rabbit kidney.
    Schwertschlag U, Stahl T, Hackenthal E.
    Prostaglandins; 1982 Jan; 23(1):129-38. PubMed ID: 7038776
    [Abstract] [Full Text] [Related]

  • 6. Single-blind study of epoprostenol and 6-keto-prostaglandin E1 in man: effects of platelet aggregation and plasma renin.
    Miyamori I, Morise T, Yasuhara S, Takeda Y, Koshida H, Takeda R.
    Br J Clin Pharmacol; 1985 Dec; 20(6):681-3. PubMed ID: 3912001
    [Abstract] [Full Text] [Related]

  • 7. A comparison of some pharmacological actions of prostaglandin E1, 6-oxo-PGE1 and PGI2.
    Adaikan PG, Tai NY, Lau LC, Karim SM, Kottegoda SR.
    Prostaglandins; 1984 Apr; 27(4):505-16. PubMed ID: 6203140
    [Abstract] [Full Text] [Related]

  • 8. Platelet sensitivity to antiaggregatory prostaglandins (PGE1,D2,I2) in patients with peripheral vascular disease.
    Fitscha P, Kaliman J, Sinzinger H.
    Am J Hematol; 1985 May; 19(1):13-9. PubMed ID: 3885723
    [Abstract] [Full Text] [Related]

  • 9. Stimulatory effects of vascular prostaglandins on the antiaggregatory activities of pentoxifylline acetylsalicylic acid combinations in vitro.
    Weithmann KU, Just M, Schlotte V, Seiffge D.
    Vasa; 1989 May; 18(4):273-6. PubMed ID: 2514520
    [Abstract] [Full Text] [Related]

  • 10. The effect of 6-oxo-prostaglandin E1 on human platelet aggregation in whole blood in-vitro.
    Wilsoncroft PS, Lofts FJ, Griffiths RJ, Moore PK.
    J Pharm Pharmacol; 1985 Feb; 37(2):139-41. PubMed ID: 2858551
    [Abstract] [Full Text] [Related]

  • 11. Stimulation of renin release by 6-oxo-prostaglandin E1 and prostacyclin.
    McGiff JC, Spokas EG, Wong PY.
    Br J Pharmacol; 1982 Jan; 75(1):137-44. PubMed ID: 7042021
    [Abstract] [Full Text] [Related]

  • 12. Refractoriness of platelets to prostaglandins after infusion in rabbits.
    Bertelé V, Stemerman M, Schafer A, Adelman B, Smith M, Fuhro R, Salzman E.
    J Lab Clin Med; 1985 Nov; 106(5):551-61. PubMed ID: 2997353
    [Abstract] [Full Text] [Related]

  • 13. PGI2 and PGE1 induce morphological alterations in human platelets similar to those of the initial phase of activation.
    Zilla P, Groscurth P, Varga G, Fischlein T, Fasol R.
    Exp Hematol; 1987 Aug; 15(7):741-9. PubMed ID: 3301381
    [Abstract] [Full Text] [Related]

  • 14. Potentiation of antiaggregating effect of prostaglandins by alpha-tocopherol and quercetin.
    Mardla V, Kobzar G, Samel N.
    Platelets; 2004 Aug; 15(5):319-24. PubMed ID: 15370103
    [Abstract] [Full Text] [Related]

  • 15. Effect of a stable prostacyclin analogue on platelet function and experimentally-induced thrombosis in the microcirculation.
    Sim AK, McCraw AP, Cleland ME, Nishio S, Umetsu T.
    Arzneimittelforschung; 1985 Aug; 35(12):1816-8. PubMed ID: 3913423
    [Abstract] [Full Text] [Related]

  • 16. Prostaglandin E1 potentiates the effects of P2Y12 blockade on ADP-mediated platelet aggregation in vitro: Insights using short thromboelastography.
    Khanna V, Armstrong PC, Warner TD, Curzen N.
    Platelets; 2015 Aug; 26(7):689-92. PubMed ID: 25734957
    [Abstract] [Full Text] [Related]

  • 17. Synergism between PGE1-metabolites(13,14-dihydro-prostaglandin E1, 15-keto prostaglandin E1, 15-keto-13,14-dihydro-prostaglandin E1) and nitric oxide (NO) on platelet aggregation.
    Katzenschlager R, Weiss K, Rogatti W, Peskar BA, Sinzinger H.
    Prostaglandins Leukot Essent Fatty Acids; 1992 Mar; 45(3):207-10. PubMed ID: 1589447
    [Abstract] [Full Text] [Related]

  • 18. Disaggregatory effects of prostaglandin E1, amrinone and milrinone on platelet aggregation in human whole blood.
    Kikura M, Kazama T, Ikeda T, Sato S.
    Platelets; 2000 Dec; 11(8):446-58. PubMed ID: 11177444
    [Abstract] [Full Text] [Related]

  • 19. The single prostacyclin receptor of gel-filtered platelets provides a correlation with antiaggregatory potency of PGI2 mimics.
    Eggerman TL, Hartzell CJ, Selfe S, Andersen NH.
    Thromb Res; 1987 Mar 01; 45(5):645-59. PubMed ID: 3296302
    [Abstract] [Full Text] [Related]

  • 20. Prostaglandin releasing polymers - stability and efficacy.
    McRea JC, Ebert CD, Kim SW.
    Trans Am Soc Artif Intern Organs; 1981 Mar 01; 27():511-6. PubMed ID: 7036503
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.